← Back to search

Valink Therapeutics

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Y CombinatorWinter 2021ActiveHealthcareTherapeuticsBiotechTherapeuticsDrug discovery

What they do

Problem

Many solid tumors remain poorly treated by existing immunotherapies and need more effective targeted cancer treatments.

Solution

Valink Therapeutics develops bispecific antibody drug-conjugates and other multi-modified antibody therapeutics that combine multispecificity, multivalency, and drug-conjugation in one scalable discovery process.

Who it's for

Pharmaceutical and biotechnology companies developing oncology therapeutics.

Founders

Arne Scheu
Founder

Rhodes Scholar & DPhil Biochemistry from the University of Oxford

LinkedIn
Irsyad Khairil
Founder

Pharma analyst with a background in protein engineering DPhil in Biochemistry from the University of Oxford

LinkedIn

Company timeline

Similar startups

Ventus Therapeutics
Structural bio platform to discover small molecules against hard-to-d…
Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Third Arc Bio
Clinical-stage multispecific antibody engineering platform for best-i…
Santa Ana Bio
Developing engineered antibody therapies for selective targeting and…
Arda Therapeutics
If these modalities have proven to be so effective (in some cases, ev…
ROME Therapeutics
Rome Therapeutics is developing novel therapies for cancer and autoim…